精锋医疗-B（02675）：手术机器人行业潜行者，机器人出海正当时

Investment Rating - The report assigns a "Buy" rating to the company, with a target price of HKD 73.85 per share based on a 30x price-to-sales (P/S) ratio for 2026 [8]. Core Insights - The company has achieved significant revenue growth, with a forecasted revenue of RMB 1.798 billion by 2028, reflecting a compound annual growth rate (CAGR) of 44.1% from 2026 to 2028 [4]. - The company is positioned as a leader in the surgical robotics industry, with multiple new products receiving regulatory approvals, enhancing its competitive edge in minimally invasive surgery [6][16]. - The overall expense ratio has been significantly adjusted, leading to improved profitability metrics, including a projected EBITDA of RMB 334 million by 2028 [4][39]. Summary by Sections Company Overview - The company, established in 2017, focuses on the design, research, and manufacturing of surgical robots, with key products like the MP1000 and SP1000 receiving various regulatory approvals in China and Europe [15][16]. - The company has successfully commercialized its products, with a reported revenue of RMB 456 million in 2025, marking a year-over-year increase of 184.8% [32]. Financial Performance - The company’s revenue from surgical robots and related accessories reached RMB 455 million in 2025, with a gross margin of 66.0%, indicating strong operational efficiency [32][38]. - The forecast for 2026 to 2028 shows a steady increase in revenue, with expected figures of RMB 848 million, RMB 1.247 billion, and RMB 1.798 billion respectively [4]. Product Development and Market Position - The company has launched several innovative products, including the CP1000 bronchial robot and the MP1000 multi-port laparoscopic robot, which have received both NMPA and CE certifications [16][23]. - The company is the only manufacturer in China and Europe to have both single-port and multi-port laparoscopic robots approved, establishing a unique market position [16]. Expense Management - The company has effectively reduced its research and development expense ratio to 40.6% in 2025, down from previous years, while maintaining a competitive edge through increased production efficiency [39]. - Management and sales expense ratios have also decreased, reflecting the company's ability to scale operations effectively while controlling costs [39].